Five months into his tenure as CEO, Paul Hudson has trimmed Sanofi’s executive team back by four. The executives departing Sanofi (Euronext:SAN; NASDAQ:SNY) are EVP, Business Transformation Dominique Carouge; EVP, CMO and Chief Digital Officer...

With its first approval for an internally developed drug, BeiGene faces tough competition as it seeks to carve out a niche for Brukinsa. But the third-to-market Btk inhibitor could have an edge on efficacy without...

Amgen is taking a hybrid approach to building out its China business that will allow it to accelerate its commercial plans in the country without biting off more than it can chew. Through the deal...

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...

Merck KGaA's deal with GlaxoSmithKline plc to develop cancer therapy M7824 enables Merck to pursue a more ambitious development plan than it could have done by going it alone, and provides a template for how...

Bankers and buysiders are not ready to call the end of the biotech bull on the heels of the sector's worst quarter in more than 13 years. But they do expect volatility to persist through...

Innovate Oncology Inc. (IOVO), New York, N.Y. Business: Cancer Appointed: Paul Hopper, former CEO of Avantogen Ltd., as chairman WIR Staff...